Blood clotting control

Patent metadata

Field	Value
Publication number	US-9545383-B2
Application number	US-201514675248-A
Country	US
Kind code	B2
Filing date	Mar 31, 2015
Priority date	Apr 1, 2014
Publication date	Jan 17, 2017
Grant date	Jan 17, 2017

Abstract

The disclosure is directed to enabling reversible, on-demand remote control of blood clotting and clot dissolution. In one embodiment, a laser at one wavelength triggers release of a DNA thrombin inhibitor from one nanorod, which acts as an anticoagulant to stop blood clotting. Another wavelength triggers release of a specific antidote, which reverses the effect of the thrombin inhibitor, restoring blood clotting.

First claim

What is claimed is:

1. A composition comprising:
a nanoparticle with a first excitation wavelength; and
a therapeutic agent selected from one of an anticoagulant and an anticoagulant antidote attached to the nanoparticle, wherein excitation of the nanoparticle with the first excitation wavelength releases the therapeutic agent.

2. The composition of claim 1 , wherein the nanoparticle is at least one of a nanobone and a nanorod.

3. The composition of claim 1 , wherein the nanoparticle is a gold nanoparticle.

4. The composition of claim 1 , wherein the therapeutic agent is attached to the nanoparticle using at least one of adsorption and covalent bonding.

5. The composition of claim 1 , wherein the therapeutic agent is released from the nanoparticle by melting the nanoparticle with the first excitation wavelength.

6. The composition of claim 1 , wherein the therapeutic agent is the anticoagulant and the anticoagulant is a thrombin inhibitor.

7. The composition of claim 6 , wherein the thrombin inhibitor is a DNA thrombin inhibitor.

8. The composition of claim 7 , wherein the DNA thrombin inhibitor is a thrombin inhibiting aptamer.

9. The composition of claim 1 , wherein the therapeutic agent is the anticoagulant antidote and the anticoagulant antidote is a DNA antidote of an anticoagulant.

10. The composition of claim 9 , wherein the DNA antidote is a DNA antidote of a DNA thrombin inhibitor.

11. The composition of claim 1 , wherein the first excitation wavelength comprises a wavelength to which tissue is transparent.

12. The composition of claim 1 , further comprising a nanoparticle with a second excitation wavelength different from the first excitation wavelength, and wherein the therapeutic agent is the anticoagulant and the anticoagulant antidote is attached to the nanoparticle with the second excitation wavelength.

13. A method for controlling clotting, the method comprising:
administering a first nanoparticle with a first excitation wavelength, wherein an anticoagulant is attached to the first nanoparticle;
administering a second nanoparticle with a second excitation wavelength different from the first excitation wavelength, wherein an anticoagulant antidote is attached to the second nanoparticle;
exciting the first nanoparticle with the first excitation wavelength to release the anticoagulant; and
exciting the second nanoparticle with the second excitation wavelength to release the anticoagulant antidote.

14. The method of claim 13 , wherein the first and second nanoparticles include at least one of a nanobone and a nanorod.

15. The method of claim 13 , wherein the first and second nanoparticles are gold nanoparticles.

16. The method of claim 13 , wherein the anticoagulant and anticoagulant antidote are attached to the first and second nanoparticles using at least one of a adsorption and covalent bonding.

17. The method of claim 13 , wherein the anticoagulant is released from the first nanoparticle by melting the first nanoparticle with the first excitation wavelength.

18. The method of claim 17 , wherein the anticoagulant antidote is released from the second nanoparticle by melting the second nanoparticle with the second excitation wavelength.

19. The method of claim 13 , wherein the anticoagulant is a thrombin inhibitor.

20. The method of claim 19 , wherein the thrombin inhibitor is a DNA thrombin inhibitor.

21. The method of claim 20 , wherein the DNA thrombin inhibitor is a thrombin inhibiting aptamer.

22. The method of claim 13 , wherein the anticoagulant antidote is a DNA antidote of a thrombin inhibitor.

23. The method of claim 13 , wherein the first excitation wavelength comprises a wavelength to which tissue is transparent.

24. The method of claim 13 , wherein exciting the first nanoparticle and/or second nanoparticle further comprises exciting the first nanoparticle and/or second nanoparticle with a laser.

Assignees

• Massachusetts Inst Technology

Inventors

• Hamad-Schifferli Kimberly
• Baxamusa Salmaan H
• De Puig Guixe Helena

Classifications

• A61K9/5115 Primary

  Inorganic compounds · CPC title

• A61K47/48884

  Human Necessities · mapped topic

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• A61N5/062

  Photodynamic therapy, i.e. excitation of an agent · CPC title

• A61K41/0028

  Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds · CPC title